Even 4th jab ‘not enough’ to tackle Omircon: Study...

Even 4th jab ‘not enough’ to tackle Omircon: Study

 International Desk daily-bangladesh.com

 Published: 05:20 PM, 18 January 2022  

Collected

Collected

Even the fourth dose of Pfizer and Moderna vaccines is not enough to deal with Covid-19. 

Although not entirely successful, an Israeli study found that the fourth dose of the vaccine was “partially effective” in preventing the virus. 

AFP reported the information in a report on Tuesday.

After taking two doses of existing vaccines for COVID prevention, people in many countries have started taking booster doses of the vaccine. Governments in Europe, America and Asia are urging citizens to take a booster dose. Booster doses have also been introduced in the subcontinent.

However, an Israeli research paper says “not only the third dose of the vaccine but also the fourth booster dose will not be completely successful in tackling COVID”. 

Researchers at the Sheba Medical Center in Israel conducted the study. However, their final report has not been released yet. They gave this information in the initial report.

According to the media, this is the first time that a Jewish medical center of that country has worked on the fourth dose of the Covid-19 vaccine. 

The report says about 150 people were vaccinated with the Pfizer-BioNTech vaccine for a trial. The US pharmaceutical company Moderna vaccine was rolled out to 120 people.

All of the 270 people who took part in the study were vaccinated with Pfizer as the third booster dose. A team who rolled out third booster doses - those who did not receive fourth doses - was also kept separate.  

The researchers found that “people who took the fourth vaccine had higher levels of antibodies”. However, it is not able to completely eliminate variants like Omicron. That is, Omicron can occur even if the fourth dose is taken. However, at the same time, it has been said that the person taking the fourth dose has more “immunity” than the person taking the third dose.

Multiple vaccine manufacturers around the world are now trying to create combined vaccines - which is expected to be more effective than current vaccines.

Some companies are trying to make a vaccine by combining the Covid-19 vaccine with the RSV vaccine for the flu. It is expected to hit the market by 2023.

Source: Deutsche Welle

DailyBangladesh/AS